Abstract Futuristic Background

Masked ImmunoCytokines

 

Interferons have direct anti-tumor activity as well as  being master regulators of immune response

IFN.png
 

Key Enabling Technology: IFN Masks

  • Immunocytokines with IFNs fused to Abs are potent anti-  cancer therapeutics, but can result in systemic IFN receptor  binding that can reduce the half-life of the therapeutic and/or  cause toxicity

  • To prevent systemic IFN receptor binding, while maintaining  anti-tumor activity, Qwixel has designed peptide masks that  are expressed on the C-terminal end of the IFN and block its  ability to bind to its receptor.

  • The masks are attached through a peptide sequence that is  sensitive to cleavage by tumor-selective proteases; thereby  allowing activation of the IFN selectively within the tumor  environment

Screen Shot 2020-03-08 at 5.33.49 PM.png
 

Three Levels of Tumor Selectivity

  • Immunocytokines with IFNs fused to Abs are potent anti-  cancer therapeutics, but can result in systemic IFN receptor  binding that can reduce the half-life of the therapeutic and/or  cause toxicity

  • To prevent systemic IFN receptor binding, while maintaining  anti-tumor activity, Qwixel has designed peptide masks that  are expressed on the C-terminal end of the IFN and block its  ability to bind to its receptor.

  • The masks are attached through a peptide sequence that is  sensitive to cleavage by tumor-selective proteases; thereby  allowing activation of the IFN selectively within the tumor  environment